ÀÇ»çȸ¼Ò°³
ȸ Ģ
°øÁö»çÇ×
ÀÓ¿øÁø¼Ò°³
Àλ縻
ÀÓ¿øÁø¾È³»
Çмú´ëȸ
»çÀüµî·Ï
Çмú´ëȸ ÀÚ·á½Ç
¼¼¹Ì³ª ¾È³»
ȸ¿ø°Ô½ÃÆÇ
ÀÚ·á½Ç
°Ô½ÃÆÇ »è°¨ÁÙÀ̱â
Áö¿ª³»°úÀÇ»çȸ ¼Ò½Ä
ÀÚ·á½Ç
°Ô½ÃÆÇ »è°¨ÁÙÀ̱â
Áö¿ª³»°úÀÇ»çȸ ¼Ò½Ä
ÀÛ¼ºÀÏ : 11-09-23 23:08
ACE inhibitorÀÎ ¶ó¹ÌÇÁ¸±À» ó¹æ ¼±È£ÇÏ´Â °æ¿ì´Â¿ä?
±Û¾´ÀÌ :
¶ó¹ÌÇÁ¸±
Á¶È¸ : 750
´ëÇк´¿ø ¼øȯ±â ó¹æÀ» º¸¸é ¶ó¹ÌÇÁ¸±ÀÌ Ã³¹æµÇ´Â °æ¿ì°¡ ¸¹Àº µ¥
ARBº¸´Ù ¶ó¹ÌÇÁ¸±ÀÌ ¼±È£µÇ´Â °æ¿ì´Â CHF³ª post MIÀÇ preload¸¦ ÁÙÀÌ´Â °æ¿ìÀÎÁö¿ä?
[ÀÌ °Ô½Ã¹°Àº °ü¸®ÀÚ´Ô¿¡ ÀÇÇØ 2016-06-24 14:55:23 À͸í°Ô½ÃÆÇ¿¡¼ À̵¿ µÊ]
DM
11-09-26 09:40
´ç´¢¹ß»ýÀ» ÇöÀúÈ÷ ÁÙ¿´±â ¶§¹®À̶ó ÀαⰡ ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù. ±âħµîÀÇ ºÎÀÛ¿ëÀÌ °áÄÚ ÀûÁö ¾ÊÀ½¿¡¼ ÂøÇÑ ÀÇ»çµéÀÌ ´ç´¢¹ß»ýÀ» ÁÙÀ̰ųª ´ç´¢È¯ÀÚ ºÐµé¿¡°Ô µµ¿òµÇ°Ô ÇÏ·Á°í ¸¹À̵é ó¹æÇÏ¿´´Ù°í »ý°¢ÇÕ´Ï´Ù.
´ç´¢¹ß»ýÀ» ÇöÀúÈ÷ ÁÙ¿´±â ¶§¹®À̶ó ÀαⰡ ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù. ±âħµîÀÇ ºÎÀÛ¿ëÀÌ °áÄÚ ÀûÁö ¾ÊÀ½¿¡¼ ÂøÇÑ ÀÇ»çµéÀÌ ´ç´¢¹ß»ýÀ» ÁÙÀ̰ųª ´ç´¢È¯ÀÚ ºÐµé¿¡°Ô µµ¿òµÇ°Ô ÇÏ·Á°í ¸¹À̵é ó¹æÇÏ¿´´Ù°í »ý°¢ÇÕ´Ï´Ù.
½ÉºÎÀü
11-09-26 09:42
½ÉºÎÀüÀÇ °æ¿ì¿¡´Â ÄÚµð¿À¹ÝÀÌ °¡Àå ¸ÕÀú ÁÖ¸ñÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª À̰͵µ ¸»±â ½ÉºÎÀüÀÇ °æ¿ì¿¡ ±¹ÇѵǴ °ÍÀ̶ó°í ¼³¸íÀ» µé¾ú½À´Ï´Ù. ÃÖ±Ù ´Ù¼öÀÇ ARB°¡ ½ÉºÎÀüÀÇ ÀûÀÀÁõÀ» °¡Áö°í ÆǸÅÇÏ°í ÀÖ½À´Ï´Ù.
½ÉºÎÀüÀÇ °æ¿ì¿¡´Â ÄÚµð¿À¹ÝÀÌ °¡Àå ¸ÕÀú ÁÖ¸ñÀ» ¹Þ¾Ò½À´Ï´Ù. ±×·¯³ª À̰͵µ ¸»±â ½ÉºÎÀüÀÇ °æ¿ì¿¡ ±¹ÇѵǴ °ÍÀ̶ó°í ¼³¸íÀ» µé¾ú½À´Ï´Ù. ÃÖ±Ù ´Ù¼öÀÇ ARB°¡ ½ÉºÎÀüÀÇ ÀûÀÀÁõÀ» °¡Áö°í ÆǸÅÇÏ°í ÀÖ½À´Ï´Ù.
ETC
11-09-26 10:06
Systolic heart failure CV events ACEI (CONSENSUS, SAVE)
ARB (Val-HeFT, CHARM)
¥â-Blocker (MERIT-HF, COMET)
Aldosterone antagonist (RALES)
Recent MI Recurrent MI or death
¥â-Blockers (ISIS)
Reduced left ventricular function after MI Recurrent MI, CHF hospitalization
==============================================
ACEI (SAVE, TRACE)
==============
Aldosterone antagonist (EPHESUS)
¥â-Blocker (CAPRICORN)
Systolic heart failure CV events ACEI (CONSENSUS, SAVE) ARB (Val-HeFT, CHARM) ¥â-Blocker (MERIT-HF, COMET) Aldosterone antagonist (RALES) Recent MI Recurrent MI or death ¥â-Blockers (ISIS) Reduced left ventricular function after MI Recurrent MI, CHF hospitalization ============================================== ACEI (SAVE, TRACE) ============== Aldosterone antagonist (EPHESUS) ¥â-Blocker (CAPRICORN)
¶ó¹ÌÇÁ¸±
11-09-26 10:34
1. °íÇ÷¾ÐȯÀÚÀÇ ½ÅÀåÀÇ º¸È£°¡ ²À ÇÊ¿äÇÑ ½ÃÁ¡¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Ù
2. ½É±Ù°æ»öÈÄ¿¡ Á½ɽDZâ´ÉÀÌ ¶³¾îÁø °æ¿ì¿¡ Á½ɽDZâ´ÉÀ¯Áö¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Ù.
3. ´ç´¢ÀÇ ¹ß»ý°¡´É¼ºÀÌ ³ôÀº ȯÀÚ¿¡°Ô ¿¹¹æÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Ù.
4. Á¦ 2 Çü ´ç´¢È¯ÀÚÀÇ ´ç Á¶Àý±â´É°È¿¡ µµ¿òÀÌ µÈ´Ù.
´Ù¸¸ Á¶ÀýµÇÁö ¾Ê´Â ±âħÀÇ ºóµµ°¡ ¹®Á¦°¡ µÈ´Ù.
1. °íÇ÷¾ÐȯÀÚÀÇ ½ÅÀåÀÇ º¸È£°¡ ²À ÇÊ¿äÇÑ ½ÃÁ¡¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Ù 2. ½É±Ù°æ»öÈÄ¿¡ Á½ɽDZâ´ÉÀÌ ¶³¾îÁø °æ¿ì¿¡ Á½ɽDZâ´ÉÀ¯Áö¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Ù. 3. ´ç´¢ÀÇ ¹ß»ý°¡´É¼ºÀÌ ³ôÀº ȯÀÚ¿¡°Ô ¿¹¹æÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Ù. 4. Á¦ 2 Çü ´ç´¢È¯ÀÚÀÇ ´ç Á¶Àý±â´É°È¿¡ µµ¿òÀÌ µÈ´Ù. ´Ù¸¸ Á¶ÀýµÇÁö ¾Ê´Â ±âħÀÇ ºóµµ°¡ ¹®Á¦°¡ µÈ´Ù.
½ÉºÎÀü
11-09-26 10:46
Table 227-4 Drugs for the Treatment of Chronic Heart Failure (EF <40%)
Diuretics
Furosemide 20–40 mg qd or bid 400 mg/da
Torsemide 10–20 mg qd bid 200 mg/da
Bumetanide 0.5–1.0 mg qd or bid 10 mg/da
Hydrochlorthiazide 25 mg qd 100 mg/da
Metolazone 2.5–5.0 mg qd or bid 20 mg/da
Angiotensin-Converting Enzyme Inhibitors
Captopril 6.25 mg tid 50 mg tid
Enalapril 2.5 mg bid 10 mg bid
Lisinopril 2.5–5.0 mg qd 20–35 mg qd
Ramipril 1.25–2.5 mg bid 2.5–5 mg bid
Trandolapril 0.5 mg qd 4 mg qd
Angiotensin Receptor Blockers
Valsartan 40 mg bid 160 mg bid
Candesartan 4 mg qd 32 mg qd
Irbesartan 75 mg qd 300 mg qdb
Losartan 12.5 mg qd 50 mg qd
Receptor Blockers
Carvedilol 3.125 mg bid 25–50 mg bid
Bisoprolol 1.25 mg qd 10 mg qd
Metoprolol succinate CR 12.5–25 mg qd Target dose 200 mg qd
Additional Therapies
Spironolactone 12.5–25 mg qd 25–50 mg qd
Eplerenone 25 mg qd 50 mg qd
Combination of hydralazine/isosorbide dinitrate 10–25 mg/10 mg tid 75 mg/40 mg tid
Fixed dose of hydralazine/isosorbide dinitrate 37.5 mg/20 mg (one tablet) tid 75 mg/40 mg (two tablets) tid
Digoxin 0.125 mg qd 0.375 mg/db
Table 227-4 Drugs for the Treatment of Chronic Heart Failure (EF <40%) Diuretics Furosemide 20–40 mg qd or bid 400 mg/da Torsemide 10–20 mg qd bid 200 mg/da Bumetanide 0.5–1.0 mg qd or bid 10 mg/da Hydrochlorthiazide 25 mg qd 100 mg/da Metolazone 2.5–5.0 mg qd or bid 20 mg/da Angiotensin-Converting Enzyme Inhibitors Captopril 6.25 mg tid 50 mg tid Enalapril 2.5 mg bid 10 mg bid Lisinopril 2.5–5.0 mg qd 20–35 mg qd Ramipril 1.25–2.5 mg bid 2.5–5 mg bid Trandolapril 0.5 mg qd 4 mg qd Angiotensin Receptor Blockers Valsartan 40 mg bid 160 mg bid Candesartan 4 mg qd 32 mg qd Irbesartan 75 mg qd 300 mg qdb Losartan 12.5 mg qd 50 mg qd Receptor Blockers Carvedilol 3.125 mg bid 25–50 mg bid Bisoprolol 1.25 mg qd 10 mg qd Metoprolol succinate CR 12.5–25 mg qd Target dose 200 mg qd Additional Therapies Spironolactone 12.5–25 mg qd 25–50 mg qd Eplerenone 25 mg qd 50 mg qd Combination of hydralazine/isosorbide dinitrate 10–25 mg/10 mg tid 75 mg/40 mg tid Fixed dose of hydralazine/isosorbide dinitrate 37.5 mg/20 mg (one tablet) tid 75 mg/40 mg (two tablets) tid Digoxin 0.125 mg qd 0.375 mg/db
À̸§
Æнº¿öµå
ºñ¹Ð±Û